World Journal of Gastrointestinal Surgery,
Год журнала:
2024,
Номер
16(8), С. 2521 - 2527
Опубликована: Авг. 16, 2024
BACKGROUND
Gastric
cancer
is
one
of
the
most
common
malignant
tumors
worldwide,
and
surgical
resection
main
ways
to
treat
gastric
cancer.
However,
immune
status
postoperative
patients
crucial
for
prognosis
survival,
cells
play
an
important
role
in
this
process.
Therefore,
it
helpful
understand
by
evaluating
levels
peripheral
blood
cells,
especially
total
T
(CD3+),
helper
(CD3+CD4+),
suppressor
(CD3+CD8+),
its
relationship
survival.
AIM
To
analyzed
with
after
surgery,
detect
cells.
METHODS
A
58
who
received
treatment
were
included
retrospective
study.
Flow
cytometry
was
used
level
analyze
correlation
between
inhibitory
explore
these
markers
patient
RESULTS
The
results
showed
that
changed
surgery.
There
a
significant
positive
(r
=
0.35,
P
<
0.01;
r
0.56,
0.01).
there
negative
-0.63,
Follow-up
survival
rate
high-level
cell
group
significantly
higher
than
low-level
(28.87
±
24.98
months
vs
18.42
16.21
months).
curve
shows
shifted
upper
right,
downward.
no
difference
time.
CONCLUSION
By
detecting
flow
cytometry,
we
can
initially
evaluate
surgery
Molecular Medicine Reports,
Год журнала:
2024,
Номер
29(3)
Опубликована: Янв. 23, 2024
Chimeric
antigen
receptor
(CAR)‑T
cell
therapy
is
an
innovative
approach
to
immune
that
works
by
modifying
the
T
cells
of
a
patient
express
CAR
protein
on
their
surface,
and
thus
induce
recognition
destruction
cancer
cells.
CAR‑T
has
shown
some
success
in
treating
hematological
tumors,
but
it
still
faces
number
challenges
treatment
solid
such
as
selection,
tolerability
safety.
In
response
these
issues,
studies
continue
improve
design
pursuit
improved
therapeutic
efficacy
future,
expected
become
important
treatment,
may
provide
new
ideas
strategies
for
individualized
immunotherapy.
The
present
review
provides
comprehensive
overview
principles,
clinical
applications,
therapy.
World Journal of Gastrointestinal Surgery,
Год журнала:
2024,
Номер
16(3), С. 700 - 709
Опубликована: Март 21, 2024
Gastric
cancer
(GC)
is
the
fifth
most
common
type
of
and
has
fourth
highest
death
rate
among
all
cancers.
There
a
lack
studies
examining
impact
liver
metastases
on
effectiveness
immunotherapy
in
individuals
diagnosed
with
GC.
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Март 13, 2025
Gastric
cancer
(GC)
ranks
as
the
fifth
most
prevalent
on
a
global
scale,
with
HER2-positive
GC
representing
distinct
subtype
that
exhibits
more
intricate
biological
characteristics.
Conventional
chemotherapy
typically
restricted
efficacy
in
management
of
GC.
In
light
incessant
advancement
molecular
targeted
therapies,
targeting
HER2
has
emerged
promising
therapeutic
approach
for
this
subtype.
The
advent
antibody-drug
conjugates
(ADCs)
and
chimeric
antigen
receptor
T-cell
therapy
(CAR-T)
furnished
novel
treatment
alternatives
Nevertheless,
owing
to
pronounced
heterogeneity
complex
tumor
microenvironment,
drug
resistance
frequently
emerges,
thereby
substantially
influencing
effectiveness
HER2-targeted
therapy.
This
article
comprehensively
summarizes
deliberates
upon
strategies
well
underlying
mechanisms.
World Journal of Gastroenterology,
Год журнала:
2024,
Номер
30(8), С. 779 - 793
Опубликована: Фев. 26, 2024
In
this
editorial,
we
comment
on
the
article
entitled
"Advances
and
key
focus
areas
in
gastric
cancer
immunotherapy:
A
comprehensive
scientometric
clinical
trial
review
(1999-2023),"
which
was
published
recent
issue
of
British Journal of Hospital Medicine,
Год журнала:
2025,
Номер
86(3), С. 1 - 24
Опубликована: Март 26, 2025
Gastric
cancer
remains
one
of
the
most
prevalent
and
lethal
malignancies
worldwide,
characterized
by
poor
survival
rates,
particularly
in
advanced
stages.
In
recent
years,
a
paradigm
shift
gastric
treatment
has
been
witnessed
with
introduction
immunotherapy
targeted
therapies.
This
review
provides
detailed
examination
current
immunotherapeutic
strategies,
including
adoptive
cell
therapy
(ACT),
immune
checkpoint
inhibitors
(ICIs),
vaccines.
Additionally,
it
explores
advancements
therapies,
focusing
on
human
epidermal
growth
factor
receptor
2
(HER2)
vascular
endothelial
(VEGFR)
signaling
pathways,
as
well
emerging
targets
such
claudin
18.2.
Clinical
trials
investigating
chimeric
antigen
T-cell
(CAR-T)
therapy,
receptor-engineered
(TCR-T)
natural
killer
(NK)
cell-based
treatments
have
shown
promise,
when
combined
conventional
chemotherapeutic
regimens.
However,
challenges
cytokine
release
syndrome,
immune-related
toxicities,
scalability
issues
remain
significant.
The
combination
therapies
represents
promising
approach
to
enhance
outcomes.
Future
directions
emphasize
need
overcome
resistance
mechanisms
refine
strategies
improve
efficacy
while
reducing
adverse
effects.
aims
elucidate
landscape
explore
their
potential
shaping
future
clinical
management
for
this
devastating
disease.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(12), С. 6471 - 6471
Опубликована: Июнь 12, 2024
Due
to
its
rapid
progression
advanced
stages
and
highly
metastatic
properties,
gastric
cancer
(GC)
is
one
of
the
most
aggressive
malignancies
fourth
leading
cause
cancer-related
deaths
worldwide.
The
process
includes
local
invasion,
metastasis
initiation,
migration
with
colonisation
at
distant
sites,
evasion
immune
response.
Tumour
growth
involves
activation
inhibitory
signals
associated
response,
also
known
as
checkpoints,
including
PD-1/PD-L1
(programmed
death
1/programmed
ligand
1),
CTLA-4
(cytotoxic
T
cell
antigen
4),
TIGIT
(T
immunoreceptor
Ig
ITIM
domains),
others.
Immune
checkpoint
molecules
(ICPMs)
are
proteins
that
modulate
innate
adaptive
responses.
While
their
expression
prominent
on
cells,
mainly
antigen-presenting
cells
(APC)
other
types
they
expressed
tumour
cells.
engagement
receptor
by
crucial
for
inhibiting
or
stimulating
cell,
which
an
extremely
important
aspect
immunotherapy.
This
narrative
review
explores
immunotherapy,
focusing
ICPMs
inhibitors
in
GC.
We
summarise
current
clinical
trials
evaluating
a
target
GC
treatment.
